Skip to main content

Table 2 Characteristics for the full and inverse probability of treatment-weighted cohort with mortality as outcome

From: Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury

  Full cohort   IPT-weighted cohort  
Early RRT (n = 621) Late RRT (n = 592) SMD Early RRT (n = 621) Late RRT (n = 592) SMD
Demographics
 Age, years, median (IQI) 67.7 (58.5–75.3) 69.0 (59.3–75.8) −0.09 68.1 (59.5–76.6) 68.7 (58.1–75.5) 0.03
 Male sex, n (%) 419 (65.5) 419 (70.8) −0.11 425 (68.5) 401 (67.7) 0.02
Surgical status, n (%)
 Nonsurgical 229 (36.9) 281 (47.5) −0.22 261 (42.1) 248 (42.0) −0.02
 Noncardiac surgery, elective 37 (6.0) 47 (7.9) −0.08 42 (6.7) 43 (7.3) −0.02
 Noncardiac surgery, acute 67 (10.8) 66 (11.1) −0.01 67 (10.8) 65 (11.0) −0.00
 Cardiac surgery, elective 100 (16.1) 66 (11.1) 0.14 84 (13.5) 74 (12.5) 0.03
 Cardiac surgery, acute 188 (30.3) 132 (22.3) 0.18 167 (26.8) 161 (27.3) −0.01
SOFA score, mean (SD) 5.5 (2.4) 4.8 (2.5) 0.29 5.2 (2.5) 5.2 (2.5) 0.01
ICU treatments, n (%)
 Vasopressors or inotropes 555 (89.4) 491 (82.9) 0.19 543 (87.4) 513 (86.6) 0.02
 Mechanical ventilation 475 (76.5) 420 (70.9) 0.13 460 (74.0) 441 (74.5) −0.01
 Extracorporeal membrane oxygenation 84 (13.5) 40 (6.8) 0.23 67 (10.7) 65 (11.0) −0.01
Laboratory values
 Creatinine, baseline, μmol/L, median (IQI) 94.9 (82.0–117.0) 90.7 (73.7–102.2) 0.19 93.2 (76.8–115.0) 92.0 (76.8–111.7) 0.01
 Potassium, mmol/L, median (IQI) 4.4 (3.9–5.0) 4.5 (4.1–5.1) −0.17 4.4 (4.0–5.0) 4.5 (4.0–5.0) −0.04
 Sodium, mmol/L, mean (SD) 139.3 (7.0) 138.8 (7.2) 0.06 138.9 (7.1) 138.8 (7.0) 0.00
Preadmission morbidity, n (%)
 Renal disease 178 (28.7) 208 (35.1) −0.14 198 (31.9) 188 (31.8) 0.00
 Diabetes 101 (16.3) 107 (18.1) −0.05 108 (17.4) 104 (17.5) −0.00
 Congestive heart disease 180 (29.0) 120 (20.3) 0.20 161 (25.9) 153 (25.9) −0.00
 Myocardial infarction 154 (24.8) 136 (23.0) 0.04 149 (24.0) 148 (25.0) −0.02
 Cerebrovascular disease 80 (12.9) 86 (14.5) −0.05 83 (13.3) 76 (12.9) 0.01
 Chronic pulmonary disease 113 (18.2) 90 (15.2) 0.08 101 (16.3) 92 (15.6) 0.02
 Liver disease 21 (3.4) 23 (3.9) −0.03 22 (3.6) 21 (3.5) 0.00
 Vascular disease 172 (27.7) 161 (27.2) 0.01 180 (29.1) 164 (27.7) 0.03
 Tumor 68 (11.0) 95 (16.0) −0.15 85 (13.7) 81 (13.7) −0.00
 Lymphoma 9 (1.4) 6 (1.0) 0.04 8 (1.3) 9 (1.5) −0.01
 Leukemia 7 (1.1) 5 (0.8) 0.03 6 (0.9) 7 (1.1) −0.02
 Metastasis 16 (2.6) 17 (2.9) −0.02 16 (2.5) 17 (2.9) −0.03
Year of treatment, n (%)
 2005–2006 95 (15.3) 149 (25.2) −0.25 121 (19.5) 115 (19.4) −0.04
 2007–2008 101 (16.3) 120 (20.3) −0.10 112 (18.0) 106 (18.0) −0.00
 2009–2010 141 (22.7) 93 (15.7) 0.18 119 (19.1) 119 (20.1) −0.03
 2011–2012 158 (25.4) 94 (15.9) 0.24 132 (21.3) 124 (20.9) 0.01
 2013–2014 126 (20.3) 136 (23.0) −0.07 138 (22.1) 128 (21.7) 0.01
  1. Abbreviations: ICU Intensive care unit, IPT Inverse probability of treatment, IQI Interquartile interval, RRT Renal replacement therapy, SMD Standard mean difference, SOFA Sequential Organ Failure Assessment, SD Standard deviation